Screening and surveillance of hepatocellular carcinoma by serum des-gamma-carboxy prothrombin in patients with glycogen storage disease type Ia

Andrea B. Schreuder; Ruben J. Overduin; Nicole Chantal Peltenburg; Lonneke de Boer; Frank A.J.A. Bodewes; Terry G.J. Derks

doi:10.1002/jmd2.12414

Screening and surveillance of hepatocellular carcinoma by serum des-gamma-carboxy prothrombin in patients with glycogen storage disease type Ia

Andrea B. Schreuder^*
, Ruben J. Overduin
, Nicole Chantal Peltenburg
, Lonneke de Boer
, Frank A.J.A. Bodewes
, Terry G.J. Derks

^*Corresponding author for this work

Internal Medicine

University Medical Centre Groningen
University of Groningen
Radboud University Medical Center

Research output: Contribution to journal › Article › Academic › peer-review

2 Citations (Scopus)

65 Downloads (Pure)

Abstract

No sensitive tumor marker for hepatocellular carcinoma (HCC) is available for patients with glycogen storage disease type Ia (GSDIa), in whom alpha-fetoprotein and carcino-embryonic antigen levels often remain normal. We describe increased levels of the HCC tumor marker des-gamma-carboxy prothrombin (DCP) in GSDIa patients with HCC. In one case DCP levels normalized after liver transplantation. We recommend including DCP as a screening HCC tumor marker in the surveillance of patients with GSDIa.

Original language	English
Pages (from-to)	207-211
Number of pages	5
Journal	JIMD Reports
Volume	65
Issue number	4
DOIs	https://doi.org/10.1002/jmd2.12414
Publication status	Published - Jul 2024

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1002/jmd2.12414Licence: CC BY

Screening and surveillance of hepatocellular carcinoma by serum des-gamma-carboxy prothrombin in patients with glycogen storage disease type IaFinal published version, 654 KBLicence: CC BY

Cite this

@article{1de1a40f47264bb69659b1ca0398ed6f,

title = "Screening and surveillance of hepatocellular carcinoma by serum des-gamma-carboxy prothrombin in patients with glycogen storage disease type Ia",

abstract = "No sensitive tumor marker for hepatocellular carcinoma (HCC) is available for patients with glycogen storage disease type Ia (GSDIa), in whom alpha-fetoprotein and carcino-embryonic antigen levels often remain normal. We describe increased levels of the HCC tumor marker des-gamma-carboxy prothrombin (DCP) in GSDIa patients with HCC. In one case DCP levels normalized after liver transplantation. We recommend including DCP as a screening HCC tumor marker in the surveillance of patients with GSDIa.",

author = "Schreuder, \{Andrea B.\} and Overduin, \{Ruben J.\} and Peltenburg, \{Nicole Chantal\} and \{de Boer\}, Lonneke and Bodewes, \{Frank A.J.A.\} and Derks, \{Terry G.J.\}",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors. JIMD Reports published by John Wiley \& Sons Ltd on behalf of SSIEM.",

year = "2024",

month = jul,

doi = "10.1002/jmd2.12414",

language = "English",

volume = "65",

pages = "207--211",

journal = "JIMD Reports",

issn = "2192-8304",

publisher = "Springer-Verlag",

number = "4",

}

TY - JOUR

T1 - Screening and surveillance of hepatocellular carcinoma by serum des-gamma-carboxy prothrombin in patients with glycogen storage disease type Ia

AU - Schreuder, Andrea B.

AU - Overduin, Ruben J.

AU - Peltenburg, Nicole Chantal

AU - de Boer, Lonneke

AU - Bodewes, Frank A.J.A.

AU - Derks, Terry G.J.

PY - 2024/7

Y1 - 2024/7

N2 - No sensitive tumor marker for hepatocellular carcinoma (HCC) is available for patients with glycogen storage disease type Ia (GSDIa), in whom alpha-fetoprotein and carcino-embryonic antigen levels often remain normal. We describe increased levels of the HCC tumor marker des-gamma-carboxy prothrombin (DCP) in GSDIa patients with HCC. In one case DCP levels normalized after liver transplantation. We recommend including DCP as a screening HCC tumor marker in the surveillance of patients with GSDIa.

AB - No sensitive tumor marker for hepatocellular carcinoma (HCC) is available for patients with glycogen storage disease type Ia (GSDIa), in whom alpha-fetoprotein and carcino-embryonic antigen levels often remain normal. We describe increased levels of the HCC tumor marker des-gamma-carboxy prothrombin (DCP) in GSDIa patients with HCC. In one case DCP levels normalized after liver transplantation. We recommend including DCP as a screening HCC tumor marker in the surveillance of patients with GSDIa.

UR - https://www.scopus.com/pages/publications/85198519111

U2 - 10.1002/jmd2.12414

DO - 10.1002/jmd2.12414

M3 - Article

C2 - 38974608

AN - SCOPUS:85198519111

SN - 2192-8304

VL - 65

SP - 207

EP - 211

JO - JIMD Reports

JF - JIMD Reports

IS - 4

ER -

Screening and surveillance of hepatocellular carcinoma by serum des-gamma-carboxy prothrombin in patients with glycogen storage disease type Ia

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this